Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.
The immunobiology of immunotherapy
Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.
EVEN MORE SEMINARS
Dr Ioanna Nixon Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde
When the oncologist meets the patient: value of compassion. How well are we doing?
Philip Beer MRCP, FRCPath, PhD ONCODNA S.A
The evolution of oncology therapeutics in the genomic era.
Dr Matt Brown The Royal Marsden Hospital
Pain in Cancer – New Horizons
Mani Naghibi St. Mark's Hospital
Eat your way to prevention, and improved treatment outcomes
Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd NHS Lothian, Scotland
Optimising Surgical Resection in Low Grade Glioma Patients